newsfilter
← Latest News
GlobeNewswire·

SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia

- Reaching the Pre-Specified 80th Event Triggers the Final Analysis of the Pivotal Phase 3 Trial - - Company to Report Topline Primary Endpoint Results this Quarter - NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) --